FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Dunne Chris T

2. Date of Event Requiring Statement (MM/DD/YYYY)
4/1/2009 

3. Issuer Name and Ticker or Trading Symbol

GENE LOGIC INC [ORXE]

(Last)        (First)        (Middle)

C/O ORE PHARMACEUTICALS INC., 610 PROFESSIONAL DRIVE, SUITE 101

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Principal Accounting Officer /

(Street)

GAITHERSBURG, MD 20879       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   7514   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Options     (1) 6/7/2009   Stock Option   1000   $20.625   D    
Incentive Stock Options     (1) 2/1/2010   Stock Option   800   $36.05   D    
Incentive Stock Options     (1) 2/22/2011   Stock Option   800   $36.05   D    
Incentive Stock Options     (1) 9/27/2011   Stock Option   480   $36.05   D    
Incentive Stock Options     (1) 6/2/2014   Stock Option   1000   $19.35   D    
Incentive Stock Options     (2) 10/17/2016   Stock Option   642   $8.45   D    
Incentive Stock Options     (1) 2/21/2017   Stock Option   8000   $9.55   D    
Incentive Stock Options     (3) 4/23/2018   Stock Option   5440   $2.20   D    

Explanation of Responses:
( 1)  Options are exercisable immediately.
( 2)  1/48th of the shares subject to the option shall vest at the end of each month, beginning with the month ending October 31, 2006.
( 3)  50% of the shares subject to the option shall vest on December 31, 2008 and the remaining 50% of the shares shall vest on December 31, 2009.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Dunne Chris T
C/O ORE PHARMACEUTICALS INC.
610 PROFESSIONAL DRIVE, SUITE 101
GAITHERSBURG, MD 20879

Principal Accounting Officer

Signatures
Chris T. Dunne 4/15/2009
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.